In order to expand the picture on the potential induction of IBD beyond the observed increased background risk in IMIDs, we conducted an in-depth systematic review and meta-analysis of studies with three different IL-17 inhibitors (SEC, IXE, BRO) in patients with chronic plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis to determine whether incidence of IBD is elevated in patients treated with IL-17 antagonists compared to those treated with placebo. Here, IL17A is linked to psoriatic arthritis.